U.S. Inflammatory Bowel Disease Treatment MarketU.S. Inflammatory Bowel Disease Treatment Market 2024-2032 Analysis: Trends, Competitor Dynamics, and Growth Opportunities
U.S. Inflammatory Bowel Disease Treatment Market by Disease Indication (Ulcerative Colitis, Crohns Disease), by Route of Administration (Oral, Injectables), by Drug Class (IL Inhibitors, TNF Inhibitors, Anti-integrin, JAK Inhibitors, Corticosteroids, ASA Drugs, Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy & Other), by Forecast 2024-2032
Base Year: 2023
100 Pages
U.S. Inflammatory Bowel Disease Treatment Market 2024-2032 Analysis: Trends, Competitor Dynamics, and Growth Opportunities
Key Insights
The U.S. Inflammatory Bowel Disease Treatment Market size was valued at USD 9.37 USD Billion in 2023 and is projected to reach USD 13.63 USD Billion by 2032, exhibiting a CAGR of 5.5 % during the forecast period. The IBD treatment incorporates a range of therapies, the aim of which is to minimize symptoms and induce remission in conditions such as Crohn's disease and ulcerative colitis. Classical approaches are based on immune suppression, anti-inflammatory Glucocorticoids , and the production of biologics that affect the pathways of inflammation. The new data show the possibilities of targeted therapies like the Janus kinase (JAK) inhibitors leading to fewer side effects with a view to the whole organism. Bowel resection, which is still a surgical intervention, may be resorted to for extreme circumstances but is not the first plan of treatment. The next wave of emerging trends promotes personalized precision medicine by using biomarkers to slice and dice the drug regimens. The US market is shown through the growing demand for biologics and target-based therapies, fuelled by the rising prevalence of diseases and the improvement of precision medicine. This results in the shift of the management of IBD towards the provision of more effective and safer treatment.
U.S. Inflammatory Bowel Disease Treatment Trends
- Shift towards personalized medicine and precision dosing
- The emergence of innovative therapies, such as JAK inhibitors
- Growing emphasis on early diagnosis and disease management
Driving Forces: What's Propelling the U.S. Inflammatory Bowel Disease Treatment Market
- Soaring Incidence of IBD: The prevalence of inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, continues to escalate in the United States.
- Demand for Advanced Therapies: Patients with IBD seek effective and well-tolerated treatment options that mitigate symptoms, improve quality of life, and prevent complications.
- Government Support for Innovation: Government agencies such as the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) provide significant funding and regulatory support for IBD research and development.
- Technological Advancements and Breakthroughs: Ongoing advancements in biotechnology and medical imaging have led to the development of novel diagnostic tools, targeted therapies, and surgical techniques.
Challenges and Restraints in U.S. Inflammatory Bowel Disease Treatment Market
- Financial Burden: The cost of IBD treatment can be substantial, posing financial challenges for patients and healthcare systems.
- Healthcare Access Disparities: Underserved areas may have limited access to specialized IBD care, leading to delayed diagnosis and suboptimal management.
- Therapeutic Gaps for Severe Cases: While treatment options exist for most IBD patients, there remains a need for effective therapies for severe and refractory cases.
Emerging Trends in U.S. Inflammatory Bowel Disease Treatment
- Development of combination therapies
- Focus on patient-centered care and disease management
- Use of artificial intelligence and machine learning for disease prediction and personalized treatment
Growth Catalysts in the U.S. Inflammatory Bowel Disease Treatment Industry
- FDA approval of novel therapies
- Partnerships and collaborations among industry players
- Increasing research and investment in innovative treatment options
Market Segmentation: U.S. Inflammatory Bowel Disease Treatment Analysis
Disease Indication:
- Ulcerative Colitis
- Crohn's Disease
Route of Administration:
- Oral
- Injectables
Drug Class:
- IL Inhibitors
- TNF Inhibitors
- Anti-integrin
- JAK Inhibitors
- Corticosteroids
- ASA Drugs
- Others
Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy & Other
Leading Players in the U.S. Inflammatory Bowel Disease Treatment Market
- AbbVie Inc.
- Takeda Pharmaceutical Company Limited
- UCB S.A.
- Bausch Health Companies Inc.
- Bristol-Myers Squibb Company
- Pfizer Inc.
- CELLTRION INC.
- Johnson & Johnson Services, Inc.
Significant Developments in the U.S. Inflammatory Bowel Disease Treatment Sector
- September 2023: FDA accepts BLA for subcutaneous administration of Takeda's ENTYVIO for Crohn's disease.
- July 2023: Coherus BioScience launches YUSIMRY at the lowest listed price for an adalimumab biosimilar in the U.S.
- July 2022: Athos Therapeutics collaborates with Lahey Hospital and Medical Center for precision medicine in inflammatory bowel disease.
Comprehensive Coverage U.S. Inflammatory Bowel Disease Treatment Market Report
The market report provides a comprehensive analysis of the U.S. inflammatory bowel disease treatment market, including:
- Market size estimation and growth forecasts
- Disease epidemiology and treatment landscape
- Market drivers, challenges, and growth opportunities
- Segment-specific market analysis
- Competitive landscape and company profiles
- Future market outlook and industry projections
Regional Insight
The U.S. is the largest market for inflammatory bowel disease treatment, followed by Europe and Asia-Pacific.
DROCT
- Drivers: Rising prevalence of inflammatory bowel diseases, advancements in treatment options, increasing healthcare expenditure
- Restraints: High cost of treatment, lack of access to healthcare services in underserved areas, limited treatment options for severe cases
- Opportunities: Development of combination therapies, focus on patient-centered care and disease management, use of artificial intelligence and machine learning for disease prediction and personalized treatment
- Challenges: High cost of treatment, lack of access to healthcare services in underserved areas, limited treatment options for severe cases
- Threats: Patent expirations, competition from biosimilars
Pricing Analysis
- Price ranges vary depending on the drug type, brand name, and route of administration.
- Injectables are generally more expensive than oral medications.
- Biosimilars offer similar efficacy to brand-name drugs at a lower cost.
Import And Export Analysis
- The U.S. imports a significant amount of inflammatory bowel disease medications.
- The export market is growing, especially in Asia-Pacific and Latin America.
Patent/Trademark Analysis
- Key patents and trademarks are held by pharmaceutical companies, including AbbVie, Takeda, and Pfizer.
- Patent expirations are expected to drive competition and price erosion in the coming years.
U.S. Inflammatory Bowel Disease Treatment Market REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2018-2032 |
| Base Year | 2023 |
| Estimated Year | 2024 |
| Forecast Period | 2024-2032 |
| Historical Period | 2018-2023 |
| Growth Rate | CAGR of 5.5% from 2018-2032 |
| Segmentation |
|
Frequently Asked Questions
Table Of Content
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Rising Technological Developments in Products to Propel Market Growth
- 3.3. Market Restrains
- 3.3.1. High Medication Costs are Likely to Restrict the Market Growth
- 3.4. Market Trends
- 3.4.1. Increasing Number of Hospitals and ASCs Identified as Significant Market Trend
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. U.S. Inflammatory Bowel Disease Treatment Market Analysis, Insights and Forecast, 2018-2030
- 5.1. Market Analysis, Insights and Forecast - by Disease Indication
- 5.1.1. Ulcerative Colitis
- 5.1.2. Crohns Disease
- 5.2. Market Analysis, Insights and Forecast - by Route of Administration
- 5.2.1. Oral
- 5.2.2. Injectables
- 5.3. Market Analysis, Insights and Forecast - by Drug Class
- 5.3.1. IL Inhibitors
- 5.3.2. TNF Inhibitors
- 5.3.3. Anti-integrin
- 5.3.4. JAK Inhibitors
- 5.3.5. Corticosteroids
- 5.3.6. ASA Drugs
- 5.3.7. Others
- 5.4. Market Analysis, Insights and Forecast - by Distribution Channel
- 5.4.1. Hospital Pharmacy
- 5.4.2. Retail Pharmacy & Other
- 5.5. Market Analysis, Insights and Forecast - by Region
- 5.5.1.
- 5.1. Market Analysis, Insights and Forecast - by Disease Indication
- 6. Northeast U.S. Inflammatory Bowel Disease Treatment Market Analysis, Insights and Forecast, 2018-2030
- 6.1. Market Analysis, Insights and Forecast - By Disease Indication
- 6.1.1. Ulcerative Colitis and Crohn’s Disease
- 6.2. Market Analysis, Insights and Forecast - By Route of Administration
- 6.2.1. Oral and Injectables
- 6.3. Market Analysis, Insights and Forecast - By Drug Class
- 6.3.1 IL Inhibitors
- 6.3.2 TNF Inhibitors
- 6.3.3 Anti-integrin
- 6.3.4 JAK Inhibitors
- 6.3.5 Corticosteroids
- 6.3.6 ASA Drugs
- 6.3.7 and Others
- 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.4.1. Hospital Pharmacy and Retail Pharmacy & Other
- 7. Southeast U.S. Inflammatory Bowel Disease Treatment Market Analysis, Insights and Forecast, 2018-2030
- 7.1. Market Analysis, Insights and Forecast - By Disease Indication
- 7.1.1. Ulcerative Colitis and Crohn’s Disease
- 7.2. Market Analysis, Insights and Forecast - By Route of Administration
- 7.2.1. Oral and Injectables
- 7.3. Market Analysis, Insights and Forecast - By Drug Class
- 7.3.1 IL Inhibitors
- 7.3.2 TNF Inhibitors
- 7.3.3 Anti-integrin
- 7.3.4 JAK Inhibitors
- 7.3.5 Corticosteroids
- 7.3.6 ASA Drugs
- 7.3.7 and Others
- 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.4.1. Hospital Pharmacy and Retail Pharmacy & Other
- 8. Midwest U.S. Inflammatory Bowel Disease Treatment Market Analysis, Insights and Forecast, 2018-2030
- 8.1. Market Analysis, Insights and Forecast - By Disease Indication
- 8.1.1. Ulcerative Colitis and Crohn’s Disease
- 8.2. Market Analysis, Insights and Forecast - By Route of Administration
- 8.2.1. Oral and Injectables
- 8.3. Market Analysis, Insights and Forecast - By Drug Class
- 8.3.1 IL Inhibitors
- 8.3.2 TNF Inhibitors
- 8.3.3 Anti-integrin
- 8.3.4 JAK Inhibitors
- 8.3.5 Corticosteroids
- 8.3.6 ASA Drugs
- 8.3.7 and Others
- 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.4.1. Hospital Pharmacy and Retail Pharmacy & Other
- 9. Southwest U.S. Inflammatory Bowel Disease Treatment Market Analysis, Insights and Forecast, 2018-2030
- 9.1. Market Analysis, Insights and Forecast - By Disease Indication
- 9.1.1. Ulcerative Colitis and Crohn’s Disease
- 9.2. Market Analysis, Insights and Forecast - By Route of Administration
- 9.2.1. Oral and Injectables
- 9.3. Market Analysis, Insights and Forecast - By Drug Class
- 9.3.1 IL Inhibitors
- 9.3.2 TNF Inhibitors
- 9.3.3 Anti-integrin
- 9.3.4 JAK Inhibitors
- 9.3.5 Corticosteroids
- 9.3.6 ASA Drugs
- 9.3.7 and Others
- 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.4.1. Hospital Pharmacy and Retail Pharmacy & Other
- 10. West U.S. Inflammatory Bowel Disease Treatment Market Analysis, Insights and Forecast, 2018-2030
- 10.1. Market Analysis, Insights and Forecast - By Disease Indication
- 10.1.1. Ulcerative Colitis and Crohn’s Disease
- 10.2. Market Analysis, Insights and Forecast - By Route of Administration
- 10.2.1. Oral and Injectables
- 10.3. Market Analysis, Insights and Forecast - By Drug Class
- 10.3.1 IL Inhibitors
- 10.3.2 TNF Inhibitors
- 10.3.3 Anti-integrin
- 10.3.4 JAK Inhibitors
- 10.3.5 Corticosteroids
- 10.3.6 ASA Drugs
- 10.3.7 and Others
- 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.4.1. Hospital Pharmacy and Retail Pharmacy & Other
- 11. Competitive Analysis
- 11.1. Market Share Analysis 2023
- 11.2. Company Profiles
- 11.2.1 AbbVie Inc. (U.S.)
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Financials (Based on Availability)
- 11.2.2 Takeda Pharmaceutical Company Limited (Tokyo)
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Financials (Based on Availability)
- 11.2.3 UCB S.A. (Belgium)
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Financials (Based on Availability)
- 11.2.4 Bausch Health Companies Inc. (Canada)
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Financials (Based on Availability)
- 11.2.5 Bristol-Myers Squibb Company (U.S.)
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Financials (Based on Availability)
- 11.2.6 Pfizer Inc. (U.S.)
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Financials (Based on Availability)
- 11.2.7 CELLTRION INC. (South Korea)
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Financials (Based on Availability)
- 11.2.8 Johnson & Johnson Services Inc. (U.S.)
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Financials (Based on Availability)
- 11.2.1 AbbVie Inc. (U.S.)
List of Figures
- Figure 1: U.S. Inflammatory Bowel Disease Treatment Market Revenue Breakdown (USD Billion, %) by Product 2023 & 2031
- Figure 2: U.S. Inflammatory Bowel Disease Treatment Market Value Share (%), by Disease Indication 2023 & 2031
- Figure 3: U.S. Inflammatory Bowel Disease Treatment Market Value Share (%), by Route of Administration 2023 & 2031
- Figure 4: U.S. Inflammatory Bowel Disease Treatment Market Value Share (%), by Drug Class 2023 & 2031
- Figure 5: U.S. Inflammatory Bowel Disease Treatment Market Value Share (%), by Distribution Channel 2023 & 2031
- Figure 6: U.S. Inflammatory Bowel Disease Treatment Market Share (%) by Company 2023
List of Tables
- Table 1: U.S. Inflammatory Bowel Disease Treatment Market Revenue USD Billion Forecast, by Disease Indication 2018 & 2031
- Table 2: U.S. Inflammatory Bowel Disease Treatment Market Revenue USD Billion Forecast, by Route of Administration 2018 & 2031
- Table 3: U.S. Inflammatory Bowel Disease Treatment Market Revenue USD Billion Forecast, by Drug Class 2018 & 2031
- Table 4: U.S. Inflammatory Bowel Disease Treatment Market Revenue USD Billion Forecast, by Distribution Channel 2018 & 2031
- Table 5: U.S. Inflammatory Bowel Disease Treatment Market Revenue USD Billion Forecast, by Region 2018 & 2031
- Table 6: U.S. Inflammatory Bowel Disease Treatment Market Revenue USD Billion Forecast, by Disease Indication 2018 & 2031
- Table 7: U.S. Inflammatory Bowel Disease Treatment Market Revenue USD Billion Forecast, by Route of Administration 2018 & 2031
- Table 8: U.S. Inflammatory Bowel Disease Treatment Market Revenue USD Billion Forecast, by Drug Class 2018 & 2031
- Table 9: U.S. Inflammatory Bowel Disease Treatment Market Revenue USD Billion Forecast, by Distribution Channel 2018 & 2031
- Table 10: U.S. Inflammatory Bowel Disease Treatment Market Revenue USD Billion Forecast, by Region 2018 & 2031
- Table 11: U.S. Inflammatory Bowel Disease Treatment Market Revenue USD Billion Forecast, by Disease Indication 2018 & 2031
- Table 12: U.S. Inflammatory Bowel Disease Treatment Market Revenue USD Billion Forecast, by Route of Administration 2018 & 2031
- Table 13: U.S. Inflammatory Bowel Disease Treatment Market Revenue USD Billion Forecast, by Drug Class 2018 & 2031
- Table 14: U.S. Inflammatory Bowel Disease Treatment Market Revenue USD Billion Forecast, by Distribution Channel 2018 & 2031
- Table 15: U.S. Inflammatory Bowel Disease Treatment Market Revenue USD Billion Forecast, by Country 2018 & 2031
- Table 16: Northeast U.S. Inflammatory Bowel Disease Treatment Market Revenue (USD Billion) Forecast, by Application 2018 & 2031
- Table 17: Southeast U.S. Inflammatory Bowel Disease Treatment Market Revenue (USD Billion) Forecast, by Application 2018 & 2031
- Table 18: Midwest U.S. Inflammatory Bowel Disease Treatment Market Revenue (USD Billion) Forecast, by Application 2018 & 2031
- Table 19: Southwest U.S. Inflammatory Bowel Disease Treatment Market Revenue (USD Billion) Forecast, by Application 2018 & 2031
- Table 20: West U.S. Inflammatory Bowel Disease Treatment Market Revenue (USD Billion) Forecast, by Application 2018 & 2031
- Table 21: U.S. Inflammatory Bowel Disease Treatment Market Revenue USD Billion Forecast, by Disease Indication 2018 & 2031
- Table 22: U.S. Inflammatory Bowel Disease Treatment Market Revenue USD Billion Forecast, by Route of Administration 2018 & 2031
- Table 23: U.S. Inflammatory Bowel Disease Treatment Market Revenue USD Billion Forecast, by Drug Class 2018 & 2031
- Table 24: U.S. Inflammatory Bowel Disease Treatment Market Revenue USD Billion Forecast, by Distribution Channel 2018 & 2031
- Table 25: U.S. Inflammatory Bowel Disease Treatment Market Revenue USD Billion Forecast, by Country 2018 & 2031
| Aspects | Details |
|---|---|
| Study Period | 2018-2032 |
| Base Year | 2023 |
| Estimated Year | 2024 |
| Forecast Period | 2024-2032 |
| Historical Period | 2018-2023 |
| Growth Rate | CAGR of 5.5% from 2018-2032 |
| Segmentation |
|
STEP 1 - Identification of Relevant Samples Size from Population Database
STEP 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Top-down and bottom-up approaches are used to validate the global market size and estimate the market size for manufactures, regional segemnts, product and application.
Note* : In applicable scenarios
STEP 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
STEP 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence
Additionally after gathering mix and scattered data from wide range of sources, data is triangull- ated and correlated to come up with estimated figures which are further validated through primary mediums, or industry experts, opinion leader.
About Market Research Forecast
MR Forecast provides premium market intelligence on deep technologies that can cause a high level of disruption in the market within the next few years. When it comes to doing market viability analyses for technologies at very early phases of development, MR Forecast is second to none. What sets us apart is our set of market estimates based on secondary research data, which in turn gets validated through primary research by key companies in the target market and other stakeholders. It only covers technologies pertaining to Healthcare, IT, big data analysis, block chain technology, Artificial Intelligence (AI), Machine Learning (ML), Internet of Things (IoT), Energy & Power, Automobile, Agriculture, Electronics, Chemical & Materials, Machinery & Equipment's, Consumer Goods, and many others at MR Forecast. Market: The market section introduces the industry to readers, including an overview, business dynamics, competitive benchmarking, and firms' profiles. This enables readers to make decisions on market entry, expansion, and exit in certain nations, regions, or worldwide. Application: We give painstaking attention to the study of every product and technology, along with its use case and user categories, under our research solutions. From here on, the process delivers accurate market estimates and forecasts apart from the best and most meaningful insights.
Products generically come under this phrase and may imply any number of goods, components, materials, technology, or any combination thereof. Any business that wants to push an innovative agenda needs data on product definitions, pricing analysis, benchmarking and roadmaps on technology, demand analysis, and patents. Our research papers contain all that and much more in a depth that makes them incredibly actionable. Products broadly encompass a wide range of goods, components, materials, technologies, or any combination thereof. For businesses aiming to advance an innovative agenda, access to comprehensive data on product definitions, pricing analysis, benchmarking, technological roadmaps, demand analysis, and patents is essential. Our research papers provide in-depth insights into these areas and more, equipping organizations with actionable information that can drive strategic decision-making and enhance competitive positioning in the market.
